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After getting approval from IRB 15 patients were treated
with the vaccine prepared from their own malignant ser-
osal fluid. This study was done 1990. These were
patients who had all conventional chemotherapy and
have failed and had progressive disease. The serosal
fluid was heat treated under aseptic condition so as to
maintain the antigenecity but to lose the virulence of
the malignant cells. The fluid then was injected subcuta-
neously half cc QOD first week and twice week second
week and then once week. The patients were informed
to report any unusual symptoms such as fever, rash or
swelling at the injection site or any systemic effects. The
patients were examined every month by the physician
and the appropriate radiological work up was done
every three months or earlier if needed. All the labora-
tory work was done to begin with and every fourth
week.
Results
One patient with advanced gastric cancer had CR for
five years, 2/4 NSCLC had partial response for 6
months, 1/4 breast cancer had PR for 5.8 months, 2/3
ovarian cancer had PR for 7.8 months and 1/2 colon
cancer had PR for 4.5 months and 1/1 pancreatic cancer
had PR for 4 months. No adverse events were noted
other than mild itching in 4 patients at the site of injec-
tion. The PR was consider if there was at least 25%
reduction in the metastatic disease. The patient with CR
lived for 5 and half years and had died at the age of 95.
Methodology
The fluid was heated at 37 degree centigrade for 45 minutes
in aliquots of 5cc test tubes in a water bath. Post heat treat-
ment was analyzed for malignant cells. The culture and sen-
sitivity was done to make sure there no was contamination.
The study on the fluid was limited as the technology was not
advanced then. But now we can determine Exons, cytokines
or genetic analysis, microRNAs.
Conclusion
This initial crude method of making the vaccine was
successful in getting response 8/15 patients, 1 patient
had very long-term response excluding her PR average
of 4 months without any side effects. Now the technol-
ogy has advanced so we may be able to isolate what
antigenic molecule we are injecting or is it the entire
cytoskeleton that is needed. Besides the patient who had
CR had gastric cancer and as we now know the cancer
genomics is more unique in gastric cancers such perso-
nalized therapy may be more specific in gastric cancer.
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